EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Modulation by Epstein–Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis

Nevena Todorović iD, Maria Raffaella Ambrosio, Amedeo Amedei iD

Pathogens · 2024

DOI: 10.3390/pathogens13100876 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, 2024. Verfasst von Nevena Todorović und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Epstein-Barr Virus Infections, Carcinogenesis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University as a “problem-driven” research projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EBV infects more than 90% of people globally, causing lifelong infection. The phases of the EBV life cycle encompass primary infection, latency, and subsequent reactivation or lytic phase. The primary infection usually happens without noticeable symptoms, commonly in early life stages. If it manifests after childhood, it could culminate in infectious mononucleosis. Regarding potential late consequences, EBV is associated with multiple sclerosis, rheumatoid arthritis, chronic active EBV infection, lymphomas, and carcinomas. Previous reports that the lytic phase plays a negligible or merely secondary role in the oncogenesis of EBV-related tumors are steadily losing credibility. The right mechanisms through which the lytic cycle contributes to carcinogenesis are still unclear, but it is now recognized that lytic genes are expressed to some degree in different cancer-type cells, implicating their role here. The lytic infection is a persistent aspect of virus activity, continuously stimulating the immune system. EBV shows different strategies to modulate and avoid the immune system, which is thought to be a key factor in its ability to cause cancer. So, the principal goal of our review is to explore the EBV’s lytic phase contribution to oncogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 4, HumanEpstein-Barr Virus InfectionsCarcinogenesisHumansVirus LatencyNeoplasmsAnimalsVirus Activation

Stichwörter der Autor:innen

EBV-related tumorsEpstein–Barr virus (EBV)immunomodulationlytic cycleoncogenesis

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
  • Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
  • Pathology Unit, Azienda Sanitaria Toscana Nord Ovest, 56121 Pisa, Italy.
  • Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 50139 Florence, Italy.

ORCID-Profile: Nevena Todorović, Amedeo Amedei

Förderung

  • University as a “problem-driven” research projects

Zitieren

APA

Todorović, N., Ambrosio, M. R., & Amedei, A. (2024). Immune Modulation by Epstein–Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis. Pathogens. https://doi.org/10.3390/pathogens13100876

Vancouver

Todorović N, Ambrosio MR, Amedei A. Immune Modulation by Epstein–Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis. Pathogens. 2024. doi:10.3390/pathogens13100876

BibTeX
@article{Todorovi2024,
  author = {Todorović, Nevena and Ambrosio, Maria Raffaella and Amedei, Amedeo},
  title = {Immune Modulation by Epstein–Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13100876}
}
Kostenlos starten →